Skip to main content Help with accessibility Skip to main navigation

December 2023 updates to the website

The website has now been updated following December's LSCMMG

The following guidelines have been added/updated:

Overactive bladder in female patients - updated

Recurrent UTI prophylactic antibiotic pathway - updated

Apomorphine shared care - update to follow

Out of area prescribing position statement - update to follow

Gender dysphoria prescribing information sheets - update to follow

Denosumab shared care - update to be published following next Clinical Effectiveness Group (CEG)

L&SC ICB recommended diabetes meters, strips and devices - update to follow 

The following medicines have been added/ updated:

Quinagolide - hyperprolactinaemia (removed)

Ibandronic acid oral - for post-menopausal osteoporosis (duplicate entry, one removed)

Warfarin - Prevention of stroke and systemic embolism in non-valvular atrial fibrillation (updated)

The following Items will be updated and added to the website following the next Commissioning Resource Group (CRG) Meeting:

Morphine Sulfate Orodispersible Tablets (Actimorph®) - severe pain and breathlessness in patients with symptoms due to a palliative (life limiting) illness

Anastrozole - primary prevention of breast cancer

Ulipristal (Esmya) - for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women who have not reached menopause when uterine fibroid embolisation and/or surgical treatment options are not suitable or have failed (RAG review)

Ibandronic acid injection - post-menopausal osteoporosis (RAG review)

Empagliflozin - chronic heart failure with preserved or mildly reduced ejection fraction (NICE TA929)

Tirzepatide - treating type 2 diabetes (NICE TA924)

Additional website updates:

The LSCMMG website has been updated to host Patient Group Directions (PGDs), please find more information under the 'LSC Resources' tab or here.